ADVERTISEMENT

pharmaceuticals

Pfizer to Halt Alzheimer’s and Parkinson’s Drug Research
Jim Daley | Jan 7, 2018 | 1 min read
The company’s recent effort to find new treatments for Alzheimer’s ended in disappointment.
Clinical Trial Reporting for Pharma-Sponsored Trials Shows Improvement
Diana Kwon | Dec 4, 2017 | 4 min read
The Good Pharma Scorecard finds some big pharmaceutical companies are meeting legal standards for disclosing results—but many studies still go unreported.
Detecting Subvisible Particles in Protein Therapeutics
The Scientist Creative Services Team in collaboration with Yokogawa Fluid Imaging Technologies | 3 min read
New flow imaging microscopy technology visualizes a broad range of subvisible particles hidden in therapeutic suspensions.  
RNA Interference Drug Excels in Clinical Trials to Treat Rare Disorder
Katarina Zimmer | Nov 3, 2017 | 2 min read
If approved, patisiran will be the first RNAi therapeutic on the market. 
Puerto Rico’s Hurricane Damage May Mean Drug Shortages
Ashley P. Taylor | Oct 11, 2017 | 2 min read
Three weeks after Hurricane Maria hit the island, pharmaceutical plants are not back up to speed.
One Size Does Not Fit All: Pharmacogenomics in Precision Medicine
The Scientist | 1 min read
Sandosh Padmanabhan and Andrew Morrow will discuss how pharmacogenomics methods improve precision medicine for cardiovascular disease treatment.
Opinion: Token Pharmacovigilance
Peter Doshi | May 23, 2017 | 3 min read
A US government website for collecting reports of side effects associated with vaccines is broken. Why has no one noticed?
Johnson & Johnson to Acquire Swiss Biotech Firm for $30 Billion
Joshua A. Krisch | Jan 26, 2017 | 1 min read
With its purchase of Actelion, Johnson & Johnson’s acquires experimental treatments for pulmonary arterial hypertension and several rare diseases.
The MSC: Regeneration Orchestrator
The Scientist Staff | 7 min read
Scientists uncover the promise of mesenchymal stem cells (MSCs), also known as medicinal signaling cells, to modulate the immune system and regenerate tissue.
Takeda to Buy Cancer Drug Maker Ariad for $5.2 Billion
Joshua A. Krisch | Jan 9, 2017 | 1 min read
The pharma giant’s purchase of the US firm includes the acquisition of investigative cancer drugs.
Drug Approval Timeline Same as 20 Years Ago
Kerry Grens | Jan 9, 2017 | 2 min read
A report finds that new medications still take about 12 years to go from patent to patient.
European Drug Regulator Releases Clinical Trial Data
Ben Andrew Henry | Oct 21, 2016 | 2 min read
In the initial steps of a campaign to make clinical reports publicly available, the European Medicines Agency has published data on two recently approved drugs.
NYU Halts Studies, Suspends Investigator
Bob Grant | Jun 28, 2016 | 1 min read
Experiments conducted at the New York University School of Medicine violated several research standards, according to US Food and Drug Administration investigators.
Another Drug Price Hike
Bob Grant | Mar 28, 2016 | 1 min read
Valeant Pharmaceuticals is criticized for jacking up the price of a drug used in assisted suicide.
Abbott Acquires Diagnostics Firm
Kerry Grens | Feb 2, 2016 | 1 min read
In a deal worth $5.8 billion, Abbott Laboratories is buying medical test–maker Alere.
Shire to Buy Baxalta for $32 Billion
Tracy Vence | Jan 11, 2016 | 1 min read
The Dublin-based pharma giant is set to acquire Baxalta, an Illinois-based Baxter spinoff, expanding its rare disease drug portfolio.
Thermo Fisher to Acquire Affymetrix
Tracy Vence | Jan 11, 2016 | 1 min read
The boards of both companies have agreed to a $1.3 billion deal, which is subject to Affymetrix shareholder approval.
Bayer Enters CRISPR Field
Karen Zusi | Dec 22, 2015 | 1 min read
The pharmaceutical company will spend $335 million on a new venture with biotech startup CRISPR Therapeutics.
First Dengue Vax Approved
Kerry Grens | Dec 11, 2015 | 2 min read
Mexico’s health ministry has OKed the vaccine for people between nine and 45 years old.
Daraprim Discounts Offered
Karen Zusi | Nov 26, 2015 | 1 min read
Turing Pharmaceuticals will soon offer discounts to hospitals for its toxoplasmosis-fighting drug, the company announced, but some say the proposed price reductions are not enough.
ADVERTISEMENT